Cargando…
Use of statins and associated factors in nonagenarians in the Community of Madrid, Spain
BACKGROUND: The role of statins in the management of dyslipidemia in elderly patients with different cardiovascular risks remains unclear. OBJECTIVE: To study use of statins and associated factors in subjects aged 90 or over in the Community of Madrid, Spain. METHODS: Observational, cross-sectional...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349136/ https://www.ncbi.nlm.nih.gov/pubmed/34363590 http://dx.doi.org/10.1007/s40520-021-01945-5 |
_version_ | 1783735503220113408 |
---|---|
author | Lahoz, Carlos Cárdenas-Valladolid, Juan Salinero-Fort, Miguel Ángel Mostaza, José María |
author_facet | Lahoz, Carlos Cárdenas-Valladolid, Juan Salinero-Fort, Miguel Ángel Mostaza, José María |
author_sort | Lahoz, Carlos |
collection | PubMed |
description | BACKGROUND: The role of statins in the management of dyslipidemia in elderly patients with different cardiovascular risks remains unclear. OBJECTIVE: To study use of statins and associated factors in subjects aged 90 or over in the Community of Madrid, Spain. METHODS: Observational, cross-sectional study that included all people aged 90 or more residing in the Community of Madrid as of December 31, 2015. The clinical information was obtained from the database that contains the electronic medical records collected by family doctors in primary care. Comorbidity data are collected according to the International Classification of Primary Care, Second Edition (ICPC-2). RESULTS: The study population comprised 59,423 subjects, with a mean age of 93.3 (2.5) years (25.8% males). Slightly more than one quarter of the population (28.2%) was in treatment with statins, 21.9% were in primary prevention, and 48.1% in secondary prevention. The multivariate analysis revealed the factors independently associated with statin treatment to be younger age, not being institutionalized, a higher Barthel score, a lower Charlson score, a higher body mass index, and a history of diabetes, dyslipidemia, chronic kidney disease, and cardiovascular disease. CONCLUSIONS: A significant percentage of nonagenarians—mainly less frail patients with more comorbidities—in the Community of Madrid receive statin treatment. No clear efficacy has been demonstrated in reducing cardiovascular events in an age group with such a short life expectancy. |
format | Online Article Text |
id | pubmed-8349136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-83491362021-08-09 Use of statins and associated factors in nonagenarians in the Community of Madrid, Spain Lahoz, Carlos Cárdenas-Valladolid, Juan Salinero-Fort, Miguel Ángel Mostaza, José María Aging Clin Exp Res Original Article BACKGROUND: The role of statins in the management of dyslipidemia in elderly patients with different cardiovascular risks remains unclear. OBJECTIVE: To study use of statins and associated factors in subjects aged 90 or over in the Community of Madrid, Spain. METHODS: Observational, cross-sectional study that included all people aged 90 or more residing in the Community of Madrid as of December 31, 2015. The clinical information was obtained from the database that contains the electronic medical records collected by family doctors in primary care. Comorbidity data are collected according to the International Classification of Primary Care, Second Edition (ICPC-2). RESULTS: The study population comprised 59,423 subjects, with a mean age of 93.3 (2.5) years (25.8% males). Slightly more than one quarter of the population (28.2%) was in treatment with statins, 21.9% were in primary prevention, and 48.1% in secondary prevention. The multivariate analysis revealed the factors independently associated with statin treatment to be younger age, not being institutionalized, a higher Barthel score, a lower Charlson score, a higher body mass index, and a history of diabetes, dyslipidemia, chronic kidney disease, and cardiovascular disease. CONCLUSIONS: A significant percentage of nonagenarians—mainly less frail patients with more comorbidities—in the Community of Madrid receive statin treatment. No clear efficacy has been demonstrated in reducing cardiovascular events in an age group with such a short life expectancy. Springer International Publishing 2021-08-07 2022 /pmc/articles/PMC8349136/ /pubmed/34363590 http://dx.doi.org/10.1007/s40520-021-01945-5 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Lahoz, Carlos Cárdenas-Valladolid, Juan Salinero-Fort, Miguel Ángel Mostaza, José María Use of statins and associated factors in nonagenarians in the Community of Madrid, Spain |
title | Use of statins and associated factors in nonagenarians in the Community of Madrid, Spain |
title_full | Use of statins and associated factors in nonagenarians in the Community of Madrid, Spain |
title_fullStr | Use of statins and associated factors in nonagenarians in the Community of Madrid, Spain |
title_full_unstemmed | Use of statins and associated factors in nonagenarians in the Community of Madrid, Spain |
title_short | Use of statins and associated factors in nonagenarians in the Community of Madrid, Spain |
title_sort | use of statins and associated factors in nonagenarians in the community of madrid, spain |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349136/ https://www.ncbi.nlm.nih.gov/pubmed/34363590 http://dx.doi.org/10.1007/s40520-021-01945-5 |
work_keys_str_mv | AT lahozcarlos useofstatinsandassociatedfactorsinnonagenariansinthecommunityofmadridspain AT cardenasvalladolidjuan useofstatinsandassociatedfactorsinnonagenariansinthecommunityofmadridspain AT salinerofortmiguelangel useofstatinsandassociatedfactorsinnonagenariansinthecommunityofmadridspain AT mostazajosemaria useofstatinsandassociatedfactorsinnonagenariansinthecommunityofmadridspain |